About the Study

Eosinophilic esophagitis is a type of white blood cells that builds up in the lining of the tube that connects your mouth to your stomach, also known as your esophagus. The buildup is due to reaction to foods, allergens or acid reflux that can inflame or injure the esophageal tissue. The only way to diagnose this disease is through a biopsy.  As the disease progressive, these damaged tissues can lead to difficulty swallowing or cause food to get stuck when you swallow.

Currently there are no FDA-approved treatments for eosinophilic esophagitis and current therapies to help manage symptoms include dietary restrictions and topical or systemic steroids. It is estimated that 1 out of 2,000 people are affected with eosinophilic esophagitis, according to the American Partnership of Eosinophilic Disorders.

Baptist Health Center for Clinical Research is currently conducting a randomized study to help manage symptoms and treat eosinophilic esophagitis. The study is randomized, double-blind, and placebo-controlled, which means you may receive the active investigational study drug or you may receive placebo and neither you nor your study doctor will know which one you receive. You will have a 2-out-of-3 chance of receiving the active study drug and a 1-out-of-3 chance of receiving placebo. The study drug (or placebo) would be administered as a monthly intravenous infusion aimed to reducing the inflammation and pain associated with the disease. The study would last approximately 33 weeks or 57 weeks, depending on the participants’ interest in an optional open-label extended dosing period during which all patients receive the active study drug. The 33 week study would include 12 visits to our office. Compensation is available for time and travel, for those who qualified.

Qualifications

  • Between the ages of 12 – 80 years old
  • Confirmed diagnosis of Eosinophilic Esophagitis
  • Please note, other conditions may apply.